CHD1 and Familial prostate cancer: CRISPR deletion of NR2F1 was able to restore enzalutamide sensitivity in androgen receptor (AR)-positive prostate cancer LNCaP cell with chromodomain helicase DNA-binding protein 1 (CHD1) knockdown [54].